FSH time-concentration profiles before and after administration of 0.25 mg cetrorelix in the gnRH-antagonist multiple-dose protocol for ovarian hyperstimulation.
OBJECTIVE
To determine FSH concentration behavior before and after cetrorelix 0.25 mg administration in the GnRH-antagonist multiple-dose protocol on day 6 of ovarian stimulation with 150-300 IU daily recombinant FSH.


METHODS
Blood samples for FSH measurements were drawn from seven women every 15 min from 8 h prior to the first cetrorelix administration in the GnRH-antagonist multiple-dose protocol until 15-32 h thereafter.


RESULTS
No significant change of FSH concentration was observed.


CONCLUSIONS
This observation indicates that no rationale exists of increasing the daily FSH dosage concomitantly to the GnRH-antagonist administration to compensate for a drop of endogenous FSH.
Griesinger
G
G
Department of Obstetrics and Gynecology, Medical University of Schleswig-Holstein, Campus Luebeck, 23538 Luebeck, Germany. georg.griesinger@frauenklinik.uni-luebeck.de
Finas
D
D
Alisch
A
A
Roiha
K
K
Schultze-Mosgau
A
A
Schröder
A K
AK
Dafopoulos
K
K
Diedrich
K
K
Felberbaum
R
R
D015415:Biomarkers / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D010062:Ovulation Induction / Q000379:methods*
D015415:Biomarkers; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; C062876:cetrorelix